Portugal

Portugal

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.91 (0.74 - 1.09) 2019 Modelled IHME
0.93 (0.76 - 1.10) 2018 Modelled IHME
0.95 (0.76 - 1.13) 2017 Modelled IHME
0.97 (0.79 - 1.13) 2016 Modelled IHME
0.98 (0.80 - 1.15) 2015 Modelled IHME
1 (0.81 - 1.16) 2014 Modelled IHME
1.01 (0.83 - 1.18) 2013 Modelled IHME
1.02 (0.85 - 1.20) 2012 Modelled IHME
1.04 (0.87 - 1.22) 2011 Modelled IHME
1.05 (0.88 - 1.24) 2010 Modelled IHME
1.06 (0.89 - 1.24) 2009 Modelled IHME
1.07 (0.89 - 1.25) 2008 Modelled IHME
1.08 (0.90 - 1.25) 2007 Modelled IHME
1.09 (0.89 - 1.27) 2006 Modelled IHME
1.1 (0.90 - 1.28) 2005 Modelled IHME
1.11 (0.92 - 1.30) 2004 Modelled IHME
1.13 (0.94 - 1.33) 2003 Modelled IHME
1.15 (0.96 - 1.37) 2002 Modelled IHME
1.17 (0.97 - 1.40) 2001 Modelled IHME
1.18 (0.97 - 1.42) 2000 Modelled IHME
1.19 (0.98 - 1.42) 1999 Modelled IHME
1.19 (0.99 - 1.41) 1998 Modelled IHME
1.2 (0.98 - 1.41) 1997 Modelled IHME
1.2 (0.98 - 1.41) 1996 Modelled IHME
1.21 (0.98 - 1.42) 1995 Modelled IHME
1.21 (0.99 - 1.42) 1994 Modelled IHME
1.22 (0.99 - 1.43) 1993 Modelled IHME
1.23 (1 - 1.45) 1992 Modelled IHME
1.24 (1 - 1.47) 1991 Modelled IHME
1.26 (1.02 - 1.50) 1990 Modelled IHME
1.45 (0.90 - 0.20) 2016 Survey/reported Carvalhana SC , 2016
0.6 (0.10 - 1.60) 2014 Survey/reported Rocha, 2017
0.89 (0.58 - 1.35) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.04 (0.02 - 0.05) 2019 Modelled IHME
0.04 (0.03 - 0.05) 2018 Modelled IHME
0.04 (0.03 - 0.05) 2017 Modelled IHME
0.04 (0.03 - 0.05) 2016 Modelled IHME
0.04 (0.03 - 0.05) 2015 Modelled IHME
0.04 (0.03 - 0.06) 2014 Modelled IHME
0.04 (0.03 - 0.06) 2013 Modelled IHME
0.04 (0.03 - 0.06) 2012 Modelled IHME
0.04 (0.03 - 0.06) 2011 Modelled IHME
0.05 (0.03 - 0.07) 2010 Modelled IHME
0.05 (0.03 - 0.07) 2009 Modelled IHME
0.05 (0.03 - 0.07) 2008 Modelled IHME
0.05 (0.04 - 0.07) 2007 Modelled IHME
0.05 (0.04 - 0.07) 2006 Modelled IHME
0.06 (0.04 - 0.08) 2005 Modelled IHME
0.07 (0.05 - 0.09) 2004 Modelled IHME
0.09 (0.06 - 0.12) 2003 Modelled IHME
0.12 (0.08 - 0.17) 2002 Modelled IHME
0.15 (0.10 - 0.21) 2001 Modelled IHME
0.18 (0.12 - 0.27) 2000 Modelled IHME
0.23 (0.15 - 0.32) 1999 Modelled IHME
0.29 (0.19 - 0.40) 1998 Modelled IHME
0.35 (0.23 - 0.48) 1997 Modelled IHME
0.41 (0.27 - 0.55) 1996 Modelled IHME
0.45 (0.30 - 0.61) 1995 Modelled IHME
0.48 (0.33 - 0.64) 1994 Modelled IHME
0.51 (0.35 - 0.68) 1993 Modelled IHME
0.54 (0.37 - 0.71) 1992 Modelled IHME
0.56 (0.39 - 0.74) 1991 Modelled IHME
0.57 (0.41 - 0.76) 1990 Modelled IHME
0.1 (0.05 - 0.17) 2015 Modelled WHO
Showing out of
Show more
Prisoners
Download
Value (%) Year Type Source
10.8 (8.10 - 14) 2008 Survey/reported Marques NM et al, 2011

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
12 (8 - 17) 2019 Modelled IHME
12 (8 - 17) 2018 Modelled IHME
12 (8 - 18) 2017 Modelled IHME
12 (8 - 17) 2016 Modelled IHME
12 (8 - 17) 2015 Modelled IHME
12 (8 - 18) 2014 Modelled IHME
12 (8 - 18) 2013 Modelled IHME
12 (9 - 18) 2012 Modelled IHME
13 (9 - 18) 2011 Modelled IHME
13 (9 - 18) 2010 Modelled IHME
13 (9 - 18) 2009 Modelled IHME
13 (9 - 18) 2008 Modelled IHME
13 (9 - 19) 2007 Modelled IHME
13 (9 - 19) 2006 Modelled IHME
13 (9 - 19) 2005 Modelled IHME
13 (9 - 19) 2004 Modelled IHME
13 (9 - 19) 2003 Modelled IHME
13 (9 - 19) 2002 Modelled IHME
13 (9 - 19) 2001 Modelled IHME
13 (9 - 19) 2000 Modelled IHME
13 (9 - 19) 1999 Modelled IHME
13 (9 - 19) 1998 Modelled IHME
13 (9 - 19) 1997 Modelled IHME
13 (9 - 19) 1996 Modelled IHME
13 (9 - 19) 1995 Modelled IHME
13 (9 - 19) 1994 Modelled IHME
13 (9 - 19) 1993 Modelled IHME
13 (9 - 19) 1992 Modelled IHME
13 (9 - 19) 1991 Modelled IHME
13 (9 - 19) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
97 2018 Survey/reported WHO/UNICEF
97 2017 Survey/reported WHO/UNICEF
97 2016 Survey/reported WHO/UNICEF
97 2015 Survey/reported WHO/UNICEF
98 2014 Survey/reported WHO/UNICEF
98 2013 Survey/reported WHO/UNICEF
97 2012 Survey/reported WHO/UNICEF
97 2011 Survey/reported WHO/UNICEF
96 2010 Survey/reported WHO/UNICEF
95 2009 Survey/reported WHO/UNICEF
95 2008 Survey/reported WHO/UNICEF
95 2007 Survey/reported WHO/UNICEF
91 2006 Survey/reported WHO/UNICEF
86 2005 Survey/reported WHO/UNICEF
86 2004 Survey/reported WHO/UNICEF
84 2003 Survey/reported WHO/UNICEF
99 2002 Survey/reported WHO/UNICEF
82 2001 Survey/reported WHO/UNICEF
64 2000 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
98 2018 Survey/reported WHO/UNICEF
98 2017 Survey/reported WHO/UNICEF
98 2016 Survey/reported WHO/UNICEF
98 2015 Survey/reported WHO/UNICEF
98 2014 Survey/reported WHO/UNICEF
98 2013 Survey/reported WHO/UNICEF
98 2012 Survey/reported WHO/UNICEF
97 2011 Survey/reported WHO/UNICEF
97 2010 Survey/reported WHO/UNICEF
96 2009 Survey/reported WHO/UNICEF
97 2008 Survey/reported WHO/UNICEF
97 2007 Survey/reported WHO/UNICEF
97 2006 Survey/reported WHO/UNICEF
94 2005 Survey/reported WHO/UNICEF
94 2004 Survey/reported WHO/UNICEF
94 2003 Survey/reported WHO/UNICEF
82 2002 Survey/reported WHO/UNICEF
70 2001 Survey/reported WHO/UNICEF
58 2000 Survey/reported WHO/UNICEF
61 1999 Survey/reported WHO/UNICEF
64 1998 Survey/reported WHO/UNICEF
49 1997 Survey/reported WHO/UNICEF
34 1996 Survey/reported WHO/UNICEF
6 1995 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
108 2017 Survey/reported EMCDDA, 2019
63 (57 - 72) 2015 Survey/reported EMCDDA, 2017
Showing out of
Show more
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
45 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2000
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.96 (0.79 - 1.16) 2019 Modelled IHME
0.96 (0.79 - 1.15) 2018 Modelled IHME
0.95 (0.78 - 1.16) 2017 Modelled IHME
0.94 (0.77 - 1.14) 2016 Modelled IHME
0.93 (0.76 - 1.14) 2015 Modelled IHME
0.93 (0.76 - 1.13) 2014 Modelled IHME
0.93 (0.76 - 1.13) 2013 Modelled IHME
0.92 (0.76 - 1.12) 2012 Modelled IHME
0.92 (0.75 - 1.12) 2011 Modelled IHME
0.92 (0.75 - 1.12) 2010 Modelled IHME
0.92 (0.75 - 1.12) 2009 Modelled IHME
0.92 (0.75 - 1.11) 2008 Modelled IHME
0.91 (0.75 - 1.11) 2007 Modelled IHME
0.91 (0.75 - 1.11) 2006 Modelled IHME
0.91 (0.75 - 1.11) 2005 Modelled IHME
0.91 (0.75 - 1.10) 2004 Modelled IHME
0.91 (0.75 - 1.10) 2003 Modelled IHME
0.91 (0.75 - 1.10) 2002 Modelled IHME
0.91 (0.75 - 1.10) 2001 Modelled IHME
0.91 (0.74 - 1.10) 2000 Modelled IHME
0.91 (0.74 - 1.10) 1999 Modelled IHME
0.91 (0.75 - 1.10) 1998 Modelled IHME
0.92 (0.76 - 1.11) 1997 Modelled IHME
0.92 (0.76 - 1.11) 1996 Modelled IHME
0.92 (0.76 - 1.12) 1995 Modelled IHME
0.92 (0.76 - 1.11) 1994 Modelled IHME
0.92 (0.76 - 1.11) 1993 Modelled IHME
0.92 (0.76 - 1.11) 1992 Modelled IHME
0.92 (0.76 - 1.12) 1991 Modelled IHME
0.92 (0.76 - 1.12) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
1.2 (0.40 - 2.50) 2017 Survey/reported Rocha, 2017
0.54 (0.20 - 0.90) 2016 Survey/reported Carvalhana SC et al, 2016
1.8 (0.50 - 2.90) 2014 Modelled Gower et al, 2014
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
87.7 (80.50 - 95) 2016 Modelled Degenhardt L et al, 2017
84.3 (80.40 - 87.70) 2013 Survey/reported EMCDDA
Showing out of
Show more
Prisoners
Download
Value (%) Year Type Source
34.4 (26.90 - 42.60) 2008 Survey/reported Marques NM et al, 2011

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
39 (29 - 48) 2019 Modelled IHME
39 (29 - 49) 2018 Modelled IHME
39 (29 - 49) 2017 Modelled IHME
39 (29 - 48) 2016 Modelled IHME
38 (29 - 48) 2015 Modelled IHME
38 (29 - 48) 2014 Modelled IHME
38 (29 - 48) 2013 Modelled IHME
38 (28 - 47) 2012 Modelled IHME
38 (28 - 47) 2011 Modelled IHME
38 (28 - 47) 2010 Modelled IHME
37 (28 - 47) 2009 Modelled IHME
37 (28 - 47) 2008 Modelled IHME
37 (28 - 47) 2007 Modelled IHME
37 (28 - 47) 2006 Modelled IHME
37 (28 - 47) 2005 Modelled IHME
37 (28 - 47) 2004 Modelled IHME
37 (28 - 46) 2003 Modelled IHME
37 (28 - 47) 2002 Modelled IHME
37 (28 - 47) 2001 Modelled IHME
37 (28 - 47) 2000 Modelled IHME
37 (28 - 47) 1999 Modelled IHME
37 (28 - 47) 1998 Modelled IHME
37 (28 - 47) 1997 Modelled IHME
37 (28 - 47) 1996 Modelled IHME
37 (28 - 47) 1995 Modelled IHME
37 (28 - 46) 1994 Modelled IHME
37 (28 - 46) 1993 Modelled IHME
37 (28 - 46) 1992 Modelled IHME
37 (28 - 47) 1991 Modelled IHME
38 (29 - 47) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 2017 Survey/reported EMCDDA, 2019
63 (57 - 72) 2015 Survey/reported EMCDDA, 2017
Showing out of
Show more
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
45 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2000
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.91 (%)
2019
(0.74 - 1.09(%))
IHME
HCV (RNA/cAg+)
0.96 (%)
2019
(0.79 - 1.16(%))
IHME

Survey/surveillance

HBV (HBsAg+)
1.45 (%)
2016
(0.9 - 0.2(%))
Carvalhana SC , 2016
HCV (anti-HCV)
1.2 (%)
2017
(0.4 - 2.5(%))
Rocha, 2017

Hepatitis related deaths (national)

Modelled

HBV
258
2019
(199 - 333)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
769
2019
(611 - 939)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.04 (%)
2019, latest modelled
(0.02 - 0.05(%))
IHME

Prevalence PWID

HCV
84.30 (%)
2013, survey/surveillance
(80.40 - 87.70(%))
EMCDDA

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
97 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
108
2017
EMCDDA, 2019
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Resources